Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.27 USD

1.27
2,935,556

-0.03 (-2.31%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $1.26 -0.01 (-0.79%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cronos (CRON) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q4 results.

Kinjel Shah headshot

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Is a Beat in Store for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.

What's in the Cards for Arcturus (ARCT) This Earnings Season?

by Zacks Equity Research

Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.

Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study

by Zacks Equity Research

AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

by Zacks Equity Research

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study

by Zacks Equity Research

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)

by Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -12.28% and 5.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Lexicon Pharmaceuticals (LXRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 4.55% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 36.84% and -17.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Lexicon (LXRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.

Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Top Ranked Value Stocks to Buy for November 13th

by Zacks Equity Research

Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 13th

Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.